The groundbreaking success of Viagra undeniably transformed the pharmaceutical landscape, but placing funds in companies primarily reliant on generic versions presents a complex picture. While early earnings were substantial, the end of patents and the rise of discounted alternatives have eroded market share. Consequently, a thorough analysis of cu